RGD Reference Report - Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. - Rat Genome Database

RGD Reference Report - Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

General

Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases.
Authors:	Ferreira, AJ Shenoy, V Qi, Y Fraga-Silva, RA Santos, RA Katovich, MJ Raizada, MK
Citation:	Ferreira AJ, etal., Exp Physiol. 2011 Mar;96(3):287-94. doi: 10.1113/expphysiol.2010.055277. Epub 2010 Dec 10.
RGD ID:	9685434
Pubmed:	PMID:21148624 (View Abstract at PubMed)
PMCID:	PMC3077555 (View Article at PubMed Central)
DOI:	DOI:10.1113/expphysiol.2010.055277 (Journal Full-text)
Our previous studies have indicated that chronic treatment with 1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one (XNT), an angiotensin-converting enzyme 2 (ACE2) activator, reverses hypertension-induced cardiac and renal fibrosis in spontaneously hypertensive rats (SHRs). Furthermore, XNT prevented pulmonary vascular remodelling and right ventricular hypertrophy and fibrosis in a rat model of monocrotaline-induced pulmonary hypertension. The aim of this study was to determine the mechanisms underlying the protective effects of XNT against cardiac fibrosis. Hydroxyproline assay was used to measure cardiac collagen content in control and XNT-treated (200 ng kg(-1) min(-1) for 28 days) SHRs. Cardiac ACE2 activity and protein levels were determined using the fluorogenic peptide assay and Western blot analysis, respectively. Extracellular signal-regulated kinases (ERKs; p44 and p42) and angiotensin II type 1 (AT(1)) receptor levels were quantified by Western blotting. Cardiac ACE2 protein levels were approximately 15% lower in SHRs compared with Wistar-Kyoto control animals (ACE2/glyceraldehyde 3-phosphate dehydrogenase ratio: Wistar-Kyoto, 1.00 +/- 0.02 versus SHR, 0.87 +/- 0.01). However, treatment of SHRs with XNT completely restored the decreased cardiac ACE2 levels. Also, chronic infusion of XNT significantly increased cardiac ACE2 activity in SHRs. This increase in ACE2 activity was associated with decreased cardiac collagen content. Furthermore, the antifibrotic effect of XNT correlated with increased cardiac angiotensin-(1-7) immunostaining, though no change in cardiac AT(1) protein levels was observed. The beneficial effects of XNT were also accompanied by a reduction in ERK phosphorylation (phospho-ERK/total ERK ratio: Wistar-Kyoto, 1.00 +/- 0.04; control SHR, 1.46 +/- 0.25; treated SHR, 0.86 +/- 0.02). Our observations demonstrate that XNT activates cardiac ACE2 and inhibits fibrosis. These effects are associated with increases in angiotensin-(1-7) and inhibition of cardiac ERK signalling.

Only show annotations with direct experimental evidence (0 objects hidden)

Object Symbol	Species	Term	Qualifier	Evidence	With	Notes	Source	Original Reference(s)
ACE2	Human	Cardiac Fibrosis	treatment	ISO	Ace2 (Rattus norvegicus)	associated with Hypertension	RGD
Ace2	Rat	Cardiac Fibrosis	treatment	IEP		associated with Hypertension	RGD
Ace2	Mouse	Cardiac Fibrosis	treatment	ISO	Ace2 (Rattus norvegicus)	associated with Hypertension	RGD

Genes (Rattus norvegicus)


Ace2 (angiotensin converting enzyme 2)

Genes (Mus musculus)


Ace2 (angiotensin converting enzyme 2)

Genes (Homo sapiens)


ACE2 (angiotensin converting enzyme 2)